Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 2
2020 7
2021 7
2022 5
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Lenabasum Reduces Porphyromonas gingivalis-Driven Inflammation.
Batool F, Gegout PY, Stutz C, White B, Kolodziej A, Benkirane-Jessel N, Petit C, Huck O. Batool F, et al. Inflammation. 2022 Aug;45(4):1752-1764. doi: 10.1007/s10753-022-01658-5. Epub 2022 Mar 11. Inflammation. 2022. PMID: 35274214
In vivo, lenabasum was injected subcutaneously in a P. gingivalis-induced calvarial abscess mouse model to assess its pro-healing effect. Concentrations of lenabasum up to 5 M were cytocompatible in all cell types. Treatment of Pg-LPS and Pg-infected EC with lena …
In vivo, lenabasum was injected subcutaneously in a P. gingivalis-induced calvarial abscess mouse model to assess its pro-healing eff …
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Werth VP, Hejazi E, Pena SM, Haber J, Zeidi M, Reddy N, Okawa J, Feng R, Bashir MM, Gebre K, Jadoo AS, Concha JSS, Dgetluck N, Constantine S, White B. Werth VP, et al. J Invest Dermatol. 2022 Oct;142(10):2651-2659.e1. doi: 10.1016/j.jid.2022.03.029. Epub 2022 Apr 29. J Invest Dermatol. 2022. PMID: 35490744 Free PMC article. Clinical Trial.
Safety and other secondary efficacy assessments were performed till day 113. RESULTS: A total of 22 subjects were randomized to lenabasum (n = 11) or placebo (n = 11). No serious or severe adverse events were related to lenabasum, and no participants discontinued th …
Safety and other secondary efficacy assessments were performed till day 113. RESULTS: A total of 22 subjects were randomized to lenabasum …
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis.
Spiera R, Kuwana M, Khanna D, Hummers L, Frech TM, Stevens W, Matucci-Cerinic M, Kafaja S, Distler O, Jun JB, Levy Y, Leszcyzński P, Gordon J, Steen V, Lee EB, Jankowski T, Litinsky I, Chung L, Hsu V, Mayes M, Sandorfi N, Simms RW, Finzel S, de Vries-Bouwstra J, Constantine S, Dgetluck N, Dinh Q, Bloom BJ, Furst DE, White B, Denton CP; RESOLVE-1 Study Group. Spiera R, et al. Arthritis Rheumatol. 2023 Sep;75(9):1608-1618. doi: 10.1002/art.42510. Epub 2023 Jun 15. Arthritis Rheumatol. 2023. PMID: 37098795 Free article. Clinical Trial.
METHODS: A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 mg, lenabasum 5 mg, or placebo, each twice daily and added to background treatments, including immunosuppressive therapies (IST). .. …
METHODS: A multinational double-blind study was conducted in 365 dcSSc patients who were randomized and dosed 1:1:1 with lenabasum 20 …
Clinical trials and novel therapeutics in dermatomyositis.
Chandra T, Aggarwal R. Chandra T, et al. Expert Opin Emerg Drugs. 2020 Sep;25(3):213-228. doi: 10.1080/14728214.2020.1787985. Epub 2020 Jul 10. Expert Opin Emerg Drugs. 2020. PMID: 32597690 Review.
EXPERT OPINION: There are various drugs being evaluated in phase II/III clinical trials that hold promise in DM. At the forefront of these are immunoglobulin, Lenabasum, and Abatacept for which phase III clinical trials are ongoing. ...
EXPERT OPINION: There are various drugs being evaluated in phase II/III clinical trials that hold promise in DM. At the forefront of these a …
Molecular Mechanisms for the Inflammation-Resolving Actions of Lenabasum.
Burstein S. Burstein S. Mol Pharmacol. 2021 Feb;99(2):125-132. doi: 10.1124/molpharm.120.000083. Epub 2020 Nov 25. Mol Pharmacol. 2021. PMID: 33239333 Review.
A first-in-class cannabinoid analog called lenabasum that is a CB2 agonist is being developed as an inflammation-resolving drug candidate. ...The synthetic nonpsychoactive cannabinoid lenabasum could provide a safe and effective drug for this purpose. ...
A first-in-class cannabinoid analog called lenabasum that is a CB2 agonist is being developed as an inflammation-resolving drug candi …
Potent T cell-mediated anti-inflammatory role of the selective CB2 agonist lenabasum in multiple sclerosis.
Tiberi M, Evron T, Saracini S, Boffa L, Mercuri NB, Chintalacharuvu SR, Atamas SP, Chiurchiù V. Tiberi M, et al. Neuropathol Appl Neurobiol. 2022 Feb;48(2):e12768. doi: 10.1111/nan.12768. Epub 2021 Oct 21. Neuropathol Appl Neurobiol. 2022. PMID: 34543449
METHODS: Mononuclear cells from 17 healthy subjects (HS) and 25 relapsing-remitting multiple sclerosis (RRMS) patients were activated in presence or absence of lenabasum and analysed by flow cytometry and qRT-PCR. EAE mice were treated with lenabasum, and clinical s …
METHODS: Mononuclear cells from 17 healthy subjects (HS) and 25 relapsing-remitting multiple sclerosis (RRMS) patients were activated in pre …
Systemic sclerosis phase III clinical trials: Hope on the horizon?
Aringer M, Denton CP. Aringer M, et al. J Scleroderma Relat Disord. 2018 Oct;3(3):193-200. doi: 10.1177/2397198318775353. Epub 2018 May 28. J Scleroderma Relat Disord. 2018. PMID: 35382012 Free PMC article. Review.
Approaches tested include the anti-B cell antibody rituximab, the anti-interleukin-6 receptor antibody tocilizumab, the antifibrotic drugs nintedanib and pirfenidone, and the cannabinoid receptor mimetic lenabasum. That all these drugs are in advanced clinical trials despi …
Approaches tested include the anti-B cell antibody rituximab, the anti-interleukin-6 receptor antibody tocilizumab, the antifibrotic drugs n …
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis.
Chmiel JF, Flume P, Downey DG, Dozor AJ, Colombo C, Mazurek H, Sapiejka E, Rachel M, Constantine S, Conley B, Dgetluck N, Dinh Q, White B, Elborn JS; Lenabasum JBT101-CF-001 Study Group. Chmiel JF, et al. J Cyst Fibros. 2021 Jan;20(1):78-85. doi: 10.1016/j.jcf.2020.09.008. Epub 2020 Oct 1. J Cyst Fibros. 2021. PMID: 33011099 Free article. Clinical Trial.
Pulmonary exacerbations (PEx) were recorded and biomarkers of blood and lung inflammation were measured. RESULTS: Of 89 subjects randomized, 51 lenabasum and 23 placebo-only subjects completed the study. No deaths or serious or severe adverse events (AE) were considered re …
Pulmonary exacerbations (PEx) were recorded and biomarkers of blood and lung inflammation were measured. RESULTS: Of 89 subjects randomized, …
Anti-inflammatory effects of lenabasum, a cannabinoid receptor type 2 agonist, on macrophages from cystic fibrosis.
Tarique AA, Evron T, Zhang G, Tepper MA, Morshed MM, Andersen ISG, Begum N, Sly PD, Fantino E. Tarique AA, et al. J Cyst Fibros. 2020 Sep;19(5):823-829. doi: 10.1016/j.jcf.2020.03.015. Epub 2020 May 6. J Cyst Fibros. 2020. PMID: 32387042 Free article.
An improvement in phagocytic activity was also observed following lenabasum treatment. Although lenabasum did not restore the impaired polarization of anti-inflammatory M2 macrophage, it reduced the levels of IL-13 and enhanced the endocytic function of CF MDMs. The …
An improvement in phagocytic activity was also observed following lenabasum treatment. Although lenabasum did not restore the …
20 results